A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

Published:2018-01-05 Issue:1 Volume:11 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Wang Amy Y.,Weiner Howard,Green Margaret,Chang Hua,Fulton Noreen,Larson Richard A.,Odenike Olatoyosi,Artz Andrew S.,Bishop Michael R.,Godley Lucy A.,Thirman Michael J.,Kosuri Satyajit,Churpek Jane E.,Curran Emily,Pettit Kristen,Stock Wendy,Liu Hongtao

Funder

University of Chicago Cancer Center Support Grant

Cancer Research Foundation Young investigator award

K12 Paul Calabresi award

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-017-0550-8.pdf

Reference33 articles.

1. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2014. Bethesda: National Cancer Institute; 2017. https://seer.cancer.gov/csr/1975_2014/ . Accessed 1 Jan 2017

2. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Michael Hutchinson R, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–11. https://doi.org/10.1182/blood.V98.5.1302 .

3. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100(12):3869–76. https://doi.org/10.1182/blood-2001-12-0354 .

4. Ishizawa J, Kojima K, Hail N, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 2015;153:25–35. https://doi.org/10.1016/j.pharmthera.2015.06.001 .

5. Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in cancer. Semin Cancer Biol. 2014;27:74–86. https://doi.org/10.1016/j.semcancer.2014.04.005 .

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia;Biomedicines;2024-08-06

2. Beyond oncology: Selinexor’s journey into anti-inflammatory treatment and long-term management;Frontiers in Immunology;2024-05-10

3. Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses;European Journal of Medicinal Chemistry;2024-02

4. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma;Blood Reviews;2024-01

5. Nuclear Transport Inhibitors;Therapeutic Strategies in Veterinary Oncology;2023-08-23